@article{0ccf531d73d94b6e9a19c884c19e802c,
title = "HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data",
abstract = "Prediction of response to anthracycline-based therapy for breast cancer is challenging. We aimed to assess the value of HER2 and TOP2A as predictive markers of response to anthracycline-based adjuvant therapy in patients with early breast cancer.",
keywords = "Anthracyclines, Antigens, Neoplasm, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Chi-Square Distribution, Clinical Trials, Phase III as Topic, DNA Topoisomerases, Type II, DNA-Binding Proteins, Disease-Free Survival, Evidence-Based Medicine, Female, Gene Amplification, Gene Deletion, Humans, In Situ Hybridization, Fluorescence, Individualized Medicine, Kaplan-Meier Estimate, Middle Aged, Patient Selection, Predictive Value of Tests, Proportional Hazards Models, Randomized Controlled Trials as Topic, Receptor, erbB-2, Risk Assessment, Risk Factors, Survival Rate, Time Factors, Treatment Outcome, Tumor Markers, Biological",
author = "\{Di Leo\}, Angelo and Christine Desmedt and Bartlett, \{John M S\} and Fanny Piette and Bent Ejlertsen and Pritchard, \{Kathleen I\} and Denis Larsimont and Christopher Poole and Jorma Isola and Helena Earl and Henning Mouridsen and O'Malley, \{Frances P\} and Fatima Cardoso and Minna Tanner and Alison Munro and Twelves, \{Chris J\} and Christos Sotiriou and Lois Shepherd and David Cameron and Piccart, \{Martine J\} and Marc Buyse and \{HER2/TOP2A Meta-analysis Study Group\}",
note = "Copyright {\textcopyright} 2011 Elsevier Ltd. All rights reserved.",
year = "2011",
month = nov,
doi = "10.1016/S1470-2045(11)70231-5",
language = "English",
volume = "12",
pages = "1134--42",
journal = "Lancet Oncology",
issn = "1470-2045",
publisher = "Elsevier Limited",
number = "12",
}